Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: Severe deterioration and morphological correlates following the loss of locus coeruleus neurons

Brain Research

Volumn 1135, Issue 1, 2007, Pages 219-229

  Fulceri, F ^a   Biagioni, F ^b   Ferrucci, M ^a   Lazzeri, G ^a   Bartalucci, A ^a   Galli, V ^a   Ruggieri, S ^b   Paparelli, A ^a   Fornai, F ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Dyskinesia; l DOPA; Noradrenaline; Parkinson's disease

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; APOFIN; APOMORPHINE; DESIPRAMINE; DOPAMINE; LEVODOPA; NEUROTRANSMITTER; NORADRENALIN; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; DYSKINESIA; LOCUS CERULEUS; MALE; NERVE CELL NECROSIS; NEUROBIOLOGY; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PULSATILE FLOW; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CELL DEATH; DESIPRAMINE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; FUNCTIONAL LATERALITY; LEVODOPA; LOCUS COERULEUS; MALE; NEURONS; NOREPINEPHRINE; OXIDOPAMINE; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; SEVERITY OF ILLNESS INDEX; TYROSINE 3-MONOOXYGENASE;

PARKINSONIA; RATTUS;

EID: 33846646618     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.12.030     Document Type: Article

References (54)

1. Alonso-Vanegas M.A., Fawcett J.P., Causing C.G., Miller F.D., and Sadikot A.F. Characterization of dopaminergic midbrain neurons in a DBH:BDNF transgenic mouse. J. Comp. Neurol. 413 (1999) 449-462
2. 1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57 (2005) 17-26
3. Bing G., Stone E.A., Zhang Y., and Filer D. Immunohistochemical studies of noradrenergic-induced expression of c-fos in the rat CNS. Brain Res. 592 (1992) 57-62
4. Bing G., Zhang Y., Watanab Y., McEwen B.S., and Stone E.A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668 (1994) 261-265
5. Bingol B., and Schuman E.M. Activity-dependent dynamics and sequestration of proteasomes in dendritic spines. Nature 441 (2006) 1144-1148
6. Blin J., Bonnet A.M., and Agid Y. Does levodopa aggravate Parkinson's disease?. Neurology 38 (1988) 1410-1416
7. Calabresi P., Fedele E., Pisani A., Fontana G., Mercuri N.B., Bernardi G., and Reiteri M. Transmitter release associated with long-term synaptic depression in rat corticostriatal slices. Eur. J. Neurosci. 7 (1995) 1889-1894
8. Calabresi P., Giacomini P., Centonze D., and Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Ann. Neurol. 47 (2000) S60-S68
9. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
10. Cirelli C., and Tononi G. Locus coeruleus control of state-dependent gene expression. J. Neurosci. 24 (2004) 5410-5419
11. Cotzias G.C., Papavasiliou P.S., and Gellene R. Experimental treatment of parkinsonism with l-DOPA. Neurology 18 (1968) 276-277
12. Del Tredici K., Rub U., De Vos R.A., Bohl J.R., and Braak H. Where does Parkinson disease pathology begin in the brain?. J. Neuropathol. Exp. Neurol. 61 (2002) 413-426
13. Ehringer H., and Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menchen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin. Wochenschr. 38 (1960) 1236-1239
14. Ferrucci M., Gesi M., Lenzi P., Soldani P., Ruffoli R., Pellegrini A., Ruggieri S., Paparelli A., and Fornai F. Noradrenergic loss enhances MDMA toxicity and induces ubiquitin-positive striatal whorls. Neurosci. Sci. 23 (2002) S75-S76
15. Fornai F., Bassi L., Torracca M., Scalori V., and Corsini G.U. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 283 (1995) 99-102
16. Fornai F., Alessandri M.G., Fascetti F., Vaglini F., and Corsini G.U. Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxylase activity in mice. J. Neurochem. 65 (1995) 704-709
17. Fornai F., Bassi L., Torracca M.T., Alessandrì M.G., Scalori V., and Corsini G.U. Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration 5 (1996) 241-249
18. Fornai F., Alessandrì M.G., Torracca M.T., Bassi L., and Corsini G.U. Effect of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J. Pharmacol. Exp. Ther. 283 (1997) 100-107
19. Fornai F., Giorgi F.S., Alessandri M.G., Giuliani M., and Corsini G.U. Effects of pretreatment with N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J. Neurochem. 72 (1999) 777-784
20. Fornai F., Lenzi P., Frenzilli G., Gesi M., Ferrucci M., Lazzeri G., Biagioni F., Nigro M., Falleni A., Giusiani M., Pellegrini A., Blandini .F., Ruggieri S., and Paparelli A. DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Psychopharmacology (Berlin) 173 (2004) 353-363
21. Fornai F., Lenzi P., Ferrucci M., Lazzeri G., Bandettini di Poggio A., Natale G., Busceti C.L., Biagioni F., Giusiani M., Ruggieri S., and Paparelli A. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull. 65 (2005) 405-413
22. German D.C., Manaye K.F., White III C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., and Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32 (1992) 667-676
23. 1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist 9 (2003) 455-462
24. Gesi M., Soldani P., Giorgi F.S., Santinami A., Bonaccorsi I., and Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. 24 (2000) 655-668
25. Giorgi F.S., Ferrucci M., Lazzeri G., Pizzanelli C., Lenzi P., Alessandrì M.G., Murri L., and Fornai F. A damage to locus coeruleus neurons converts sporadic seizures into self-sustaining limbic status epilepticus. Eur. J. Neurosci. 17 (2003) 2593-2601
26. Henry B., Fox S.H., Peggs D., Crossman A.R., and Brotchie J.M. The alpha2-adrenergic receptor antagonism with idazoxan reduces dyskinesia and enhances anti parkinsonian actions of l-DOPA in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14 (1999) 744-753
27. Hokfelt T., and Ungerstedt U. Specificity of 6-hydroxydopamine induced degeneration of central monoamine neurones: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system. Brain Res. 60 (1973) 269-297
28. Hornykiewicz O., and Pifl C. The validity of the MPTP primate model from neurochemical pathology of idiopathic Parkinson's disease. In: Briley M., and Marien M. (Eds). Noradrenergic Mechanisms in Parkinson's Disease (1994), CRC Press, Boca Raton 59-71
29. Kilbourn M.R., Sherman P., and Abbot L.C. Reduced MPTP neurotoxicity in the striatum of the mutant mouse tottering. Synapse 30 (1998) 205-210
30. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
31. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
32. Marien M., Briley M., and Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236 (1993) 487-489
33. Marien M.R., Colpaert F.C., and Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 45 (2004) 38-78
34. Mavridis M., Degryse A.D., Lategan A.J., Marien M.R., and Colpaert F.C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41 (1991) 507-523
35. Nikaido T., Akiyama M., Moriya T., and Shibata S. Sensitized increase of period gene expression in the mouse caudate/putamen caused by repeated injection of methamphetamine. Mol. Pharmacol. 59 (2001) 894-900
36. Patrick G.N. Synapse formation and plasticity: recent insights from the perspective of the ubiquitin proteasome system. Curr. Opin. Neurobiol. 16 (2006) 90-94
37. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (2005), Academic Press, San Diego
38. Picconi B., Pisani A., Barone I., Bonsi P., Centonze D., Bernardi G., and Calabresi P. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 26 (2005) 779-783
39. Pifl C., Schingnitz G., and Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44 (1991) 591-605
40. Ponzio F., Hallman H., and Jonsson G. Noradrenaline and dopamine interaction in rat brain during development. Med. Biol. 59 (1981) 161-169
41. Poewe W.H., Lees A.J., and Stern G.M. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann. Neurol. 23 (1988) 73-78
42. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Bejjani B., Fabre N., Montastruc J.L., and Agid Y. Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesia in patients with Parkinson's disease. Mov. Disord. 16 (2001) 708-713
43. Rothman R.B., Jayanthi S., Wang X., Dersch C.M., Cadet J., Prisinzano T., Rice K.C., and Baumann M.H. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse 50 (2003) 233-239
44. Setsuie R., Kabuta T., and Wada K. Does proteasome inhibition decrease or accelerate toxin-induced dopaminergic neurodegeneration?. J. Pharmacol. Sci. 97 (2005) 457-460
45. Shults C. Lewy bodies. Proc. Natl. Acad. Sci. 103 (2006) 1661-1668
46. Srinivasan J., and Schmidt W.J. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur. J. Neurosci. 17 (2003) 2586-2592
47. Srinivasan J., and Schmidt W.J. Behavioural and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Behav. Brain. Res. 151 (2004) 191-199
48. Srinivasan J., and Schmidt W.J. Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav. Brain. Res. 154 (2004) 353-363
49. Stone E.A., and Ariano M.A. Are glial cells targets of the central noradrenergic system? A review of the evidence. Brain Res. Brain. Res. Rev. 14 (1989) 297-309
50. Tretiakoff, C. 1919. Contribution à l'étude de l'Anatomie du Locus Niger de Sommering avec quelques déductions relatives à la pathogenie des troubles du tonus musculaire de la maladie de Parkinson. Thèse de Paris.
51. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand., Suppl. 367 (1971) 95-122
52. Vitalis T., Cases O., and Parnavelas J.G. Development of the dopaminergic neurons in the rodent brainstem. Exp. Neurol. 191 (2005) S104-S112
53. Yi J.J., and Ehlers M.D. Ubiquitin and protein turnover in synapse function. Neuron 47 (2005) 629-632
54. Zarow C., Lyness S.A., Mortimer J.A., and Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60 (2003) 337-341